No Data
No Data
Cabio Biotech(Wuhan) (688089): Performance meets expectations, overseas growth rate shines.
This report summary: The performance of the company in the first half of 24H1 has shown high growth, in line with expectations, with a bright increase in overseas revenue. The company has benefited from the surge in international major customer orders, the new national standard, and the transition of domestic major customer production capacity, resulting in both revenue growth and improved profitability. Investment highlights: Investment advice:
Jiabiyou Biotechnology (Wuhan) Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Jiabiyou Biotechnology (Wuhan) Co., Ltd.
Cabio Biotech(Wuhan) (688089.SH): net income of 67.889 million yuan in the first half of the year, a year-on-year increase of 94.82%.
格隆汇August 27th丨Cabio Biotech (Wuhan) (688089.SH) announced its semi-annual report, with revenue of 0.26 billion yuan, a year-on-year increase of 31.23%, net income of 67.889 million yuan, a year-on-year increase of 94.82%, non-net profit of 53.007 million yuan, a year-on-year increase of 132.57%, and basic earnings per share of 0.40 yuan.
Cabio Biotech (688089.SH) released its semi-annual performance with a net income of 67.889 million yuan, a year-on-year increase of 94.82%.
Cabio Biotech (688089.SH) disclosed its semi-annual report for 2024, with the company realizing revenue of 2... in the reporting period.
Express News | Cabio Biotech(Wuhan): Intends to repurchase shares with 15 million to 30 million yuan.
No Data
No Data